北京福元医药股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日、2025 年 11 月 14 日分别召开第三届董事会第三次会议和 2025 年第二次临时股东会，审议 通过了《关于取消监事会、增加董事会席位、修订<公司章程>并办理工商变更登记 的议案》，同意取消监事会，《监事会议事规则》相应废止，新增 1 名职工代表董 事，对《公司章程》部分条款进行修订，并办理工商备案手续。公司于 2025 年 11 月 14 日召开职工代表大会，选举王斌超先生为公司第三届董事会职工董事。具体内 容详见公司披露于上海证券交易所网站的相关公告。 公司于近日完成了相关工商备案登记及《公司章程》的备案手续。本次备案的 事项主要为取消监事会、《公司章程》及公司董事的信息变更备案。除上述事项外， 公司《营业执照》记载的其他工商登记事项未发生变更。 特此公告。 北京福元医药股份有限公司董事会 2025 年 12 月 19 日 证券代码：601089 证券简称：福元医药 公告编号：临 2025-081 北京福元医药股份有限公司 关于公司完成工商备案登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

证券日报网讯 12月8日，新和成（002001）在互动平台回答投资者提问时表示，浙江爱生系本公司控股 股东新和成控股集团有限公司控制的另一家上市公司"福元医药（601089）"（股票代码601089）的子公 司。 ...

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received approval for clinical trials of Ketoprofen Gel Patch from the National Medical Products Administration (NMPA) [1][2] Group 1: Clinical Trial Approval - The drug name is Ketoprofen Gel Patch, with the notification number 2025LP03166, and it is classified as a Class 3 chemical drug [2][3] - The approved indications include pain relief and anti-inflammatory treatment for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, tennis elbow, muscle pain, and post-injury swelling and pain [1][3] Group 2: R&D Investment - Fuyuan Pharmaceutical has invested approximately RMB 3.9676 million (about 0.4 million USD) in the research and development of the Ketoprofen Gel Patch [3] Group 3: Market Situation - As of 2024, the sales revenue of Ketoprofen Gel Patch in China is approximately RMB 49.58 million (about 4.96 million USD), with significant sales in urban public hospitals and county-level public hospitals [6] - In the first half of 2025, the sales revenue increased to approximately RMB 76.44 million (about 7.64 million USD) [7] Group 4: Regulatory Pathway - The clinical trial application has been approved, and the product must undergo clinical research and receive further approval from the NMPA before it can be marketed [7]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-080 北京福元医药股份有限公司 关于酮洛芬凝胶贴膏获得药物临床试验批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司全资子公司福元药业有限公司 （以下简称"福元药业"）收到了国家药品监督管理局（以下简称"国 家药监局"）核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知 书》。现将有关情况公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：酮洛芬凝胶贴膏（以下简称"本品"） 通知书编号：2025LP03166 制剂剂型：贴膏剂 申请适应症：用于下列疾病和症状的镇痛及消炎：骨关节炎、肩 周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎（网球肘等）、肌 肉痛、外伤后肿胀及疼痛。 申请人：福元药业有限公司 注册分类：化学药品 3 类 申请事项：境内生产药品注册临床试验 大市场酮洛芬凝胶贴膏的销售额约为7,644万元，其中城市公立医院和 县级公立医院销售额为6,620万元，城市社区中心和乡镇卫生院销售额 为806万 ...

福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节 炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给 药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76 万元(未经审计)。 福元医药（601089）(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称"福元药业") 收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。 ...

福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节 炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给 药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76 万元(未经审计)。 智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称"福元 药业")收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。 ...

Group 1 - The core viewpoint of the news is that Fuyuan Pharmaceutical's stock has increased by 5.01%, reaching a price of 25.76 yuan per share, with a trading volume of 432 million yuan and a turnover rate of 3.65%, resulting in a total market capitalization of 12.365 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, is located in Tongzhou District, Beijing, and was listed on June 30, 2022. The company's main business involves the research, production, and sales of pharmaceutical preparations and medical devices, with pharmaceutical preparations accounting for 94.09% of revenue and medical devices 6.00% [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, a fund under E Fund ranks as a significant shareholder. The E Fund Healthcare Industry Mixed A (110023) entered the top ten circulating shareholders in the third quarter, holding 2.5638 million shares, which represents 0.53% of the circulating shares. The estimated floating profit today is approximately 3.1535 million yuan [2] - The E Fund Healthcare Industry Mixed A (110023) was established on January 28, 2011, with a latest scale of 3.802 billion yuan. Year-to-date returns are 39.49%, ranking 1421 out of 8130 in its category; the one-year return is 35.06%, ranking 1969 out of 8054; and since inception, the return is 324.9% [2] - The fund manager of E Fund Healthcare Industry Mixed A is Yang Zhenshao, who has been in the position for 9 years and 102 days. The total asset scale under management is 9.816 billion yuan, with the best fund return during the tenure being 215.53% and the worst being -12.11% [2]

Core Viewpoint - Fu Yuan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 61.36% and a recent uptick in trading activity, indicating strong market interest and potential investment opportunities [1][2]. Company Overview - Fu Yuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is located in Tongzhou District, Beijing. The company specializes in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1][2]. Financial Performance - For the period from January to September 2025, Fu Yuan Pharmaceutical reported a revenue of 2.52 billion yuan, a year-on-year decrease of 1.04%, and a net profit attributable to shareholders of 375 million yuan, down 6.39% compared to the previous year [2][3]. - The company has distributed a total of 661 million yuan in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Fu Yuan Pharmaceutical was 22,700, a decrease of 3.39% from the previous period. The average number of circulating shares per shareholder increased by 3.51% to 21,153 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 4.25 million shares, a reduction of 1.25 million shares from the previous period. New entrants include E Fund Healthcare Industry Mixed A and Ping An New Xin Pioneer Mixed A, holding 2.56 million and 2.12 million shares, respectively [3]. Market Activity - On November 27, Fu Yuan Pharmaceutical's stock price rose by 2.04% to 25.03 yuan per share, with a trading volume of 384 million yuan and a turnover rate of 3.25%, resulting in a total market capitalization of 12.01 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent occurrence on September 5, where it recorded a net buy of -42.23 million yuan [1].

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Core Points - The Shanghai Composite Index closed at 3864.18 points, below the five-day moving average, with a decline of 0.15% [1] - The total trading volume of A-shares reached 1,797.19 billion yuan [1] - A total of 693 A-shares broke through the five-day moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Mingwei Electronics (688699) saw a price increase of 20.01% with a deviation rate of 15.61% [1] - Dongxin Co., Ltd. (688110) also increased by 20.00%, with a deviation rate of 14.05% [1] - Ningbo Color Masterbatch (301019) rose by 20.00%, showing a deviation rate of 12.63% [1] Trading Activity - The trading turnover rate for Mingwei Electronics was 6.94% [1] - Dongxin Co., Ltd. had a turnover rate of 11.72% [1] - Ningbo Color Masterbatch recorded a turnover rate of 16.34% [1] Deviation Rate Rankings - Other notable stocks with high deviation rates include: - Huanle Home (300997) with a deviation rate of 12.38% [1] - Zhu Laoliu (920726) at 10.64% [1] - Haitong Development (603162) at 8.63% [1]